3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors
作者:Craig J. Kutz、Steven L. Holshouser、Ethan A. Marrow、Patrick M. Woster
DOI:10.1039/c4md00283k
日期:——
Compounds 6 and 7 represent the first reversible LSD1 inhibitors with minimal cytotoxicity in vitro.
化合物6和7是首批可逆的LSD1抑制剂,且在体外具有极小的细胞毒性。
QUINOLINYL AND BENZOTHIAZOLYL MODULATORS
申请人:McGee Lawrence R.
公开号:US20090221635A1
公开(公告)日:2009-09-03
Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ. In particular, the compounds of the invention modulate the function of PPARγ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.